BioCentury
ARTICLE | Finance

Spain’s biggest venture round yet goes to Splicebio: Venture Report

Plus: Scorpion spinout Antares raises $177M series A, French biotechs Elkedonia and Enterome raise venture cash and more

June 13, 2025 1:25 AM UTC

A $135 million series B round will make Splicebio the best-funded biotech start-up ever in Spain, allowing the company to advance its clinical program for Stargardt disease while also driving its earlier-stage pipeline.

A syndicate led by EQT Life Sciences and Sanofi Ventures is backing Barcelona-based Splicebio S.L. in the new round as it conducts the Phase I/II ASTRA study of SB-007. The therapy delivers a payload that would be too large for a single adeno-associated viral (AAV) vector; SB-007 instead delivers a pair of AAV vectors carrying portions of the cargo, along with engineered inteins that reconstitute the large ABCA4 protein in vivo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article